White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Show more
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
GSK plc (GSKN) currently trades at 878.50 MXN, while our model-based Fair Value estimate is 925.55 MXN, so the stock looks roughly fairly valued today (gap 5.1%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 1,167 MXN per share, and 15 of the 24 models we run sit above the 878.50 MXN price.
Bear case: the Asset-Based group reads lowest at 131.75 MXN, and 9 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 594.21 MXN (bear) to 1,370 MXN (bull), the price of 878.50 MXN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
GSK plc reported revenue of £32.7B in FY2025 versus £34.1B in FY2021, a compound −1.1%/yr. Reported net income was £5.7B in FY2025, compounding +6.9%/yr from FY2021.
Key figures
Market cap 3.5T MXN (≈ $194B) · P/E ratio 13.4 · P/S ratio 2.34 · EPS (TTM) 65.75 MXN · Dividend yield 0.1% · Net margin 17.5% · Return on equity 40.9% · Return on assets (EBIT) 10.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 5%, GSKN screens cheaper than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (49.21 MXN per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
531.84 MXN
784.01 MXN
1,199 MXN
80
Growth DCF
555.92 MXN
798.32 MXN
1,174 MXN
78
Owner Earnings
567.46 MXN
833.18 MXN
1,270 MXN
76
All 24 models by family
DCF Models
FCF DCF
531.84 MXN
784.01 MXN
1,199 MXN
80
Owner Earnings
567.46 MXN
833.18 MXN
1,270 MXN
76
5Y Revenue Exit
596.45 MXN
961.21 MXN
1,450 MXN
72
5Y EBITDA Exit
847.20 MXN
1,394 MXN
2,057 MXN
74
5Y P/E Exit
732.56 MXN
1,196 MXN
1,699 MXN
70
10Y Revenue Exit
543.10 MXN
860.27 MXN
1,234 MXN
66
10Y EBITDA Exit
720.81 MXN
1,148 MXN
1,651 MXN
68
10Y P/E Exit
650.00 MXN
1,016 MXN
1,405 MXN
64
Earnings-Based
Graham-Dodd
466.69 MXN
881.77 MXN
1,097 MXN
66
EPV
727.65 MXN
870.67 MXN
995.81 MXN
74
Dividend Discount
Gordon GGM
282.67 MXN
385.08 MXN
489.11 MXN
69
DDM Multi-Stage
282.67 MXN
391.45 MXN
520.02 MXN
67
Multiples
P/E Multiple
1,132 MXN
1,510 MXN
1,887 MXN
63
P/S Multiple
875.04 MXN
1,167 MXN
1,458 MXN
58
P/B Multiple
663.64 MXN
884.86 MXN
1,106 MXN
55
EV/EBIT
1,146 MXN
1,571 MXN
1,997 MXN
66
EV/EBITDA
1,212 MXN
1,660 MXN
2,108 MXN
67
EV/Revenue
693.22 MXN
1,046 MXN
1,399 MXN
53
Asset-Based
NCAV (Graham)
98.32 MXN
131.75 MXN
196.63 MXN
54
Growth DCF
Growth DCF
555.92 MXN
798.32 MXN
1,174 MXN
78
Rev-Margin DCF
596.45 MXN
970.60 MXN
1,398 MXN
72
Economic Profit
Residual Income
372.79 MXN
436.70 MXN
676.42 MXN
75
ROIC Compounder
748.20 MXN
921.76 MXN
1,094 MXN
72
Growth Earnings
Growth-Adj P/E
807.60 MXN
1,154 MXN
1,500 MXN
67
Open the full fair value analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is GSK plc (GSKN) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of 925.55 MXN versus a price of 878.50 MXN, about +5% upside (fairly valued).
What is the fair value of GSKN?
Our model-based fair value for GSK plc is 925.55 MXN (as of Sep 29, 2026), built from audited fundamentals. The current price: 878.50 MXN.
What is the quality score of GSKN?
GSK plc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GSK plc (GSKN)?
Our model-based price target is the fair value of 925.55 MXN (as of Sep 29, 2026) from 24 valuation models. Cautious scenario 594.21 MXN, optimistic scenario 1,370 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the GSK plc stock forecast for 2026?
Our models put fair value at 925.55 MXN, about +5% upside versus a price of 878.50 MXN (fairly valued). Cautious scenario 594.21 MXN, optimistic scenario 1,370 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of GSK plc (GSKN)?
GSK plc reported trailing-twelve-month revenue of about £32.8B (latest available figure, as of Sep 29, 2026).
Does GSK plc pay a dividend?
GSK plc currently shows a dividend yield of about 0.08% relative to its recent price (as of Sep 29, 2026).
What growth is priced into GSK plc (GSKN)?
For today's price to be fair in a discounted-cash-flow model, GSK plc would have to grow free cash flow by +20.1 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.9 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of GSKN use?
Our models discount GSK plc at 10.0 %: a base by market capitalisation (large), damped by beta 0.30, country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GSK plc that is +20.1 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has GSK plc (GSKN) delivered so far?
Over the past 5 years revenue at GSK plc grew -0.9 % a year. The price currently implies +20.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GSK plc (GSKN) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into GSK plc (+20.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GSK plc (GSKN)?
The free-cash-flow yield on the price is 3.26 %: that much free cash flow GSK plc produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GSK plc (GSKN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GSK plc it is 925.55 MXN per share (as of Sep 29, 2026), against a price of 878.50 MXN. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is GSK plc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, GSKN trades below its calculated fair value: price 878.50 MXN, fair value 925.55 MXN, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GSKN?
No. The price is what the market pays today (878.50 MXN); the fair value is what the company's own numbers justify (925.55 MXN). For GSK plc the two are 47.05 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is GSK plc worth?
The market values GSK plc at about 3.5T MXN (market capitalisation, as of Sep 29, 2026). Per share that is 878.50 MXN; our models calculate a fair value of 925.55 MXN per share.
What do the bullish and bearish scenarios say about GSKN?
Our models span a range for GSK plc: cautious scenario 594.21 MXN, base 925.55 MXN, optimistic 1,370 MXN per share (as of Sep 29, 2026, price 878.50 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is GSKN from its 52-week high?
GSK plc trades at 878.50 MXN, about 15% below its 52-week high of 1,031 MXN and 20% above the low of 730.72 MXN (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 925.55 MXN is for.
Which stocks are comparable to GSK plc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GSK plc stock attractive at the current price?
The data as of Sep 29, 2026: price 878.50 MXN, calculated fair value 925.55 MXN (+5%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GSKN calculated?
We run GSK plc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 925.55 MXN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. GSK plc currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of GSK plc (GSKN)?
The closing price on Sep 30, 2026 was 878.50 MXN. Our model-based fair value is 925.55 MXN, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GSK plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (594.21 MXN to 1,370 MXN) leaves room in how you read the outcome.
Key figures of GSK plc
How large is the market capitalisation of GSK plc (GSKN)?
The market capitalisation of GSK plc is 3.5T MXN (≈ $194B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of GSK plc (GSKN)?
The price-to-earnings ratio of GSK plc is 13.4. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of GSK plc (GSKN)?
The price-to-sales ratio of GSK plc is 2.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GSK plc (GSKN)?
Earnings per share at GSK plc are 65.75 MXN (price ÷ EPS = P/E 13.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GSK plc (GSKN)?
The dividend yield of GSK plc is 0.1% (payout 1.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GSK plc (GSKN)?
The net margin of GSK plc is 17.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GSK plc (GSKN)?
The return on equity (ROE) of GSK plc is 40.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GSK plc (GSKN)?
On an EBIT basis the return on assets of GSK plc is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GSK plc (GSKN)?
The operating margin of GSK plc is 36.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GSK plc (GSKN)?
Revenue at GSK plc is growing +1.5% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GSK plc (GSKN)?
Earnings per share at GSK plc are growing +8.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GSK plc (GSKN) carry?
The net debt of GSK plc is £13.7B (fiscal year 2025, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
